Orient Pharma Co. Ltd.
Orient Pharma Co., Ltd. engages in the development of new drugs in Taiwan and internationally. It offers cardiovascular drugs, such as Pitator and Tonvasca for lipid suppression, as well as Zulitor, a lipid lowering drug; psychotropic drugs, including Trokendi XR extended, Methydur, and powder and solvent for prolonged-release suspension for injection. The company was founded in 2008 and is based… Read more
Orient Pharma Co. Ltd. (4166) - Net Assets
Latest net assets as of June 2024: NT$1.77 Billion TWD
Based on the latest financial reports, Orient Pharma Co. Ltd. (4166) has net assets worth NT$1.77 Billion TWD as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$2.60 Billion) and total liabilities (NT$831.38 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$1.77 Billion |
| % of Total Assets | 68.05% |
| Annual Growth Rate | 1.69% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 28.69 |
Orient Pharma Co. Ltd. - Net Assets Trend (2019–2023)
This chart illustrates how Orient Pharma Co. Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Orient Pharma Co. Ltd. (2019–2023)
The table below shows the annual net assets of Orient Pharma Co. Ltd. from 2019 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | NT$1.67 Billion | +53.27% |
| 2022-12-31 | NT$1.09 Billion | -2.33% |
| 2021-12-31 | NT$1.12 Billion | -8.34% |
| 2020-12-31 | NT$1.22 Billion | -22.06% |
| 2019-12-31 | NT$1.56 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Orient Pharma Co. Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 27621200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$2.23 Billion | 133.51% |
| Other Comprehensive Income | NT$-3.83 Million | -0.23% |
| Other Components | NT$1.13 Billion | 67.66% |
| Total Equity | NT$1.67 Billion | 100.00% |
Orient Pharma Co. Ltd. Competitors by Market Cap
The table below lists competitors of Orient Pharma Co. Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Klingelnberg AG
SW:KLIN
|
$41.57 Million |
|
Etteplan Oyj
HE:ETTE
|
$41.57 Million |
|
1ST SUMMIT BANCORP of Johnstown Inc
PINK:FSMK
|
$41.58 Million |
|
SBI Investment KOREA Co. Ltd
KQ:019550
|
$41.60 Million |
|
Groupe Sfpi
PA:SFPI
|
$41.55 Million |
|
Oregon Pacific Bancorp
PINK:ORPB
|
$41.54 Million |
|
BitFuFu Inc. Class A Ordinary Shares
NASDAQ:FUFU
|
$41.53 Million |
|
Scicom MSC Bhd
KLSE:0099
|
$41.53 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Orient Pharma Co. Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 1,089,926,000 to 1,670,492,000, a change of 580,566,000 (53.3%).
- Net income of 22,288,000 contributed positively to equity growth.
- Other comprehensive income decreased equity by 940,000.
- Other factors increased equity by 559,218,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$22.29 Million | +1.33% |
| Other Comprehensive Income | NT$-940.00K | -0.06% |
| Other Changes | NT$559.22 Million | +33.48% |
| Total Change | NT$- | 53.27% |
Book Value vs Market Value Analysis
This analysis compares Orient Pharma Co. Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.33x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 3.95x to 3.33x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | NT$6.31 | NT$24.95 | x |
| 2020-12-31 | NT$7.19 | NT$24.95 | x |
| 2021-12-31 | NT$5.97 | NT$24.95 | x |
| 2022-12-31 | NT$5.83 | NT$24.95 | x |
| 2023-12-31 | NT$7.50 | NT$24.95 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Orient Pharma Co. Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.33%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.50%
- • Asset Turnover: 0.35x
- • Equity Multiplier: 1.53x
- Recent ROE (1.33%) is above the historical average (-9.00%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -20.40% | -56.86% | 0.23x | 1.59x | NT$-299.55 Million |
| 2020 | -14.08% | -41.59% | 0.24x | 1.43x | NT$-293.12 Million |
| 2021 | -9.20% | -22.15% | 0.26x | 1.58x | NT$-214.24 Million |
| 2022 | -2.64% | -5.62% | 0.28x | 1.70x | NT$-137.75 Million |
| 2023 | 1.33% | 2.50% | 0.35x | 1.53x | NT$-144.76 Million |
Industry Comparison
This section compares Orient Pharma Co. Ltd.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,528,453,600
- Average return on equity (ROE) among peers: 3.91%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Orient Pharma Co. Ltd. (4166) | NT$1.77 Billion | -20.40% | 0.47x | $41.55 Million |
| Grape King Bio Ltd (1707) | $11.79 Billion | 12.28% | 0.30x | $413.97 Million |
| Standard Chemical & Pharmaceutical Co Ltd (1720) | $8.14 Billion | 10.26% | 0.37x | $160.24 Million |
| Maywufa Co Ltd (1731) | $2.11 Billion | 8.22% | 0.51x | $41.33 Million |
| Allied Biotech Corporation (1780) | $1.17 Billion | 8.33% | 0.78x | $47.92 Million |
| ScinoPharm Taiwan Ltd (1789) | $9.38 Billion | 5.16% | 0.21x | $180.77 Million |
| GeneFerm Biotechnology Co Ltd (1796) | $396.19 Million | 1.14% | 1.48x | $24.30 Million |
| Easywell Biomedicals Inc. (1799) | $696.90 Million | -39.00% | 0.68x | $62.14 Million |
| LIWANLI Innovation Co Ltd (3054) | $799.59 Million | 4.48% | 0.55x | $49.55 Million |
| YungShin Global Holding Corp (3705) | $4.70 Billion | 6.21% | 0.18x | $292.12 Million |
| TTY Biopharm Co Ltd (4105) | $6.11 Billion | 22.00% | 0.56x | $486.74 Million |